Sucampo Pharma Americas, LLC clinical trials
Acquired by Keenova Therapeutics plc, Feb 13, 2018 · source ↗
The registry lists 17 studies whose lead sponsor is Sucampo Pharma Americas, LLC. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 21, 2020.
Before and after it joined Keenova Therapeutics plc
- First submitted before Sucampo Pharma Americas, LLC became part of Keenova Therapeutics plc
- 17
- First submitted after Sucampo Pharma Americas, LLC became part of Keenova Therapeutics plc
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Sucampo Pharma Americas, LLC17 studies
Something wrong with this grouping? Tell us on the Keenova Therapeutics plc page.
Studies
Recruiting first, then most recently updated. Showing 17 of 17. All Keenova Therapeutics plc studies →
- Lubiprostone in Children With Functional ConstipationCompletedNCT02042183Phase 3
Sponsor listed in the registry: Sucampo Pharma Americas, LLC · First submitted before Sucampo Pharma Americas, LLC became part of Keenova Therapeutics plc
- Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional ConstipationCompletedNCT02766777Phase 3
Sponsor listed in the registry: Sucampo Pharma Americas, LLC · First submitted before Sucampo Pharma Americas, LLC became part of Keenova Therapeutics plc
- Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy VolunteersCompletedNCT03010631Phase 3
Sponsor listed in the registry: Sucampo Pharma Americas, LLC · First submitted before Sucampo Pharma Americas, LLC became part of Keenova Therapeutics plc
- Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)CompletedNCT01298219Phase 3
Sponsor listed in the registry: Sucampo Pharma Americas, LLC · First submitted before Sucampo Pharma Americas, LLC became part of Keenova Therapeutics plc
- Lubiprostone for Children With ConstipationCompletedNCT02138136Phase 3
Sponsor listed in the registry: Sucampo Pharma Americas, LLC · First submitted before Sucampo Pharma Americas, LLC became part of Keenova Therapeutics plc
- Opioid-induced Bowel Dysfunction: Long-Term Assessment of LubiprostoneCompletedNCT00620061Phase 3
Sponsor listed in the registry: Sucampo Pharma Americas, LLC · First submitted before Sucampo Pharma Americas, LLC became part of Keenova Therapeutics plc
- Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to PlaceboCompletedNCT03097861Phase 3
Sponsor listed in the registry: Sucampo Pharma Americas, LLC · First submitted before Sucampo Pharma Americas, LLC became part of Keenova Therapeutics plc
- Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel SyndromeTerminatedNCT02544152Phase 2
Sponsor listed in the registry: Sucampo Pharma Americas, LLC · First submitted before Sucampo Pharma Americas, LLC became part of Keenova Therapeutics plc
- Cobiprostone Prevention of NSAID-induced Gastroduodenal InjuryCompletedNCT00597818Phase 2
Sponsor listed in the registry: Sucampo Pharma Americas, LLC · First submitted before Sucampo Pharma Americas, LLC became part of Keenova Therapeutics plc
- Safety and Efficacy of Lubiprostone in Pediatric Patients With ConstipationCompletedNCT00452335Phase 4
Sponsor listed in the registry: Sucampo Pharma Americas, LLC · First submitted before Sucampo Pharma Americas, LLC became part of Keenova Therapeutics plc
- Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With ConstipationCompletedNCT00399542Phase 3
Sponsor listed in the registry: Sucampo Pharma Americas, LLC · First submitted before Sucampo Pharma Americas, LLC became part of Keenova Therapeutics plc
- Opioid-induced Bowel Dysfunction: Pivotal Assessment of LubiprostoneCompletedNCT00595946Phase 3
Sponsor listed in the registry: Sucampo Pharma Americas, LLC · First submitted before Sucampo Pharma Americas, LLC became part of Keenova Therapeutics plc
- A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular DegenerationCompletedNCT01379560Phase 2
Sponsor listed in the registry: Sucampo Pharma Americas, LLC · First submitted before Sucampo Pharma Americas, LLC became part of Keenova Therapeutics plc
- Opioid-induced Bowel Dysfunction Pivotal Assessment of LubiprostoneCompletedNCT00597428Phase 3
Sponsor listed in the registry: Sucampo Pharma Americas, LLC · First submitted before Sucampo Pharma Americas, LLC became part of Keenova Therapeutics plc
- Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and ChemotherapyTerminatedNCT02542215Phase 2
Sponsor listed in the registry: Sucampo Pharma Americas, LLC · First submitted before Sucampo Pharma Americas, LLC became part of Keenova Therapeutics plc
- Efficacy and Safety of Cobiprostone in Patients With Portal HypertensionTerminatedNCT00737594Phase 2
Sponsor listed in the registry: Sucampo Pharma Americas, LLC · First submitted before Sucampo Pharma Americas, LLC became part of Keenova Therapeutics plc
- Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With ConstipationCompletedNCT00380250Phase 3
Sponsor listed in the registry: Sucampo Pharma Americas, LLC · First submitted before Sucampo Pharma Americas, LLC became part of Keenova Therapeutics plc